Publications by authors named "Chrysavgi Giannaki"
Article Synopsis
- The Covid-19 pandemic made it hard for hospitals to care for patients with severe lung problems, especially in Intensive Care Units (ICUs).
- This study looked at how sounds from patients’ lungs could help doctors understand their lung damage and predict how long they would stay in the ICU and their chances of survival.
- The researchers found that certain lung sounds, like “squawks” and “crackles,” were important because they related to how patients were doing and could help doctors make better decisions about their care.
Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance.
View Article and Find Full Text PDFVaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients.
Penelope-Georgia Papayanni Dimitrios Chasiotis Kiriakos Koukoulias Aphrodite Georgakopoulou Anastasia Iatrou Chrysavgi Giannaki
Clin Infect Dis
December 2021
Article Synopsis
- The SARS-CoV-2 pandemic has highlighted the urgent need for effective COVID-19 therapies, leading researchers to explore T-cell immunity in diverse groups, including unexposed donors, infected individuals, and vaccinated individuals.
- The study found a direct link between T-cell response strength and patient outcomes, indicating that weak T-cell responses in hospitalized patients correlated with a higher risk of severe outcomes, while strong responses could be produced from recovered and vaccinated donors.
- The findings suggest potential for developing T-cell therapies, emphasizing the importance of robust T-cell immunity in managing COVID-19, while also noting the limitations of T-cell responses in critical patients and those exposed to other coronaviruses.